Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies

NCT06719141 is registered in ClinicalTrials.gov with Longboard Pharmaceuticals as lead sponsor.

NCT NCT06719141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06719141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathies
Lead sponsor
Longboard Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 11, 2024
Completion date
November 30, 2026
Enrollment
367 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathy